Free insulin-like growth factors - Measurements and relationships to growth hormone secretion and glucose homeostasis

Growth Hormone and IGF Research

Volumn 14, Issue 5, 2004, Pages 337-375

  Frystyk, Jan ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Free IGF I; Free IGF II; IGFBPs; Immunoradiometric assay; Total IGF I; Ultrafiltration

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; FATTY ACID; GLUCOSE; GROWTH FACTOR RECEPTOR; GROWTH HORMONE; INSULIN; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADOLESCENT; ADULT; ANOREXIA NERVOSA; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; IMMUNORADIOMETRIC ASSAY; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; ULTRAFILTRATION;

ARTERIOSCLEROSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS;

EID: 4444284454     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ghir.2004.06.001     Document Type: Review

References (327)

1. Thissen J.P. Ketelslegers J.M. Underwood L.E. Nutritional regulation of the insulin-like growth factors Endocr. Rev. 15 1994 80-101
2. Jones J.I. Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions Endocr. Rev. 16 1995 3-34
3. Rajaram S. Baylink D.J. Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions Endocr. Rev. 18 1997 801-831
4. Hwa V. Oh Y. Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily Endocr. Rev. 20 1999 761-787
5. Zapf, J. Froesch, E.R. Schmid, C. Metabolic effects of IGFs in: Rosenfeld R.G. Roberts C.T. Jr. (Eds.) Contemporary Endocrinology: The IGF System (1999) 577-616 Humana Press
6. Khandwala H.M. McCutcheon I.E. Flyvbjerg A. Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth Endocr. Rev. 21 2000 215-244
7. Vaessen N. Heutink P. Janssen J.A. Witteman J.C. Testers L. Hofman A. Lamberts S.W. Oostra B.A. Pols H.A. van Duijn C.M. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction Diabetes 50 2001 637-642
8. De Meyts P. Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design Nat. Rev. Drug Discov. 1 2002 769-783
9. Moschos S.J. Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications Oncology 63 2002 317-332
10. Juul A. Scheike T. Davidsen M. Gyllenborg J. Jørgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study Circulation 106 2002 939-944
11. LeRoith D. Werner H. Beitner Johnson D. Roberts C.T. Jr. Molecular and cellular aspects of the insulin-like growth factor-I receptor Endocr. Rev. 16 1995 143-163
12. LeRoith D. Bondy C. Yakar S. Liu J.L. Butler A. The somatomedin hypothesis: 2001 Endocr. Rev. 22 2001 53-74
13. Firth S.M. Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins Endocr. Rev. 23 2002 824-854
14. Yakar S. Liu J.L. Stannard B. Butler A. Accili D. Sauer B. LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I Proc. Natl. Acad. Sci. USA 96 1999 7324-7329
15. Takada M. Nakanome H. Kishida M. Hirose S. Hasegawa T. Hasegawa Y. Measurement of free insulin-like growth factor-I using immunoradiometric assay J. Immunoassay 15 1994 263-276
16. Frystyk J. Skjærbæk C. Dinesen B. Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum FEBS Lett. 348 1994 185-191
17. Bang P. Ahlsen M. Berg U. Carlsson-Skwirut C. Free insulin-like growth factor I: are we hunting a ghost? Horm. Res. 55 Suppl. 2 2001 84-93
18. Schoenle E.J. Zenobi P.D. Torresani T. Werder E.A. Zachmann M. Froesch E.R. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance Diabetologia 34 1991 675-679
19. Cheetham T.D. Jones J. Taylor A.M. Holly J. Matthews D.R. Dunger D.B. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus Diabetologia 36 1993 678-681
20. Laager R. Keller U. Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and type 2 (non-insulin-dependent) diabetic subjects Diabetologia 36 1993 966-971
21. Clemmons D.R. Moses A.C. McKay M.J. Sommer A. Rosen D.M. Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity J. Clin. Endocrinol. Metab. 85 2000 1518-1524
22. Baxter R.C. Inhibition of the insulin-like growth factor (IGF)-IGF-binding protein interaction Horm. Res. 55 Suppl. 2 2001 68-72
23. Clemmons D.R. Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency Horm. Res. 55 Suppl. 2 2001 73-79
24. Guler H.P. Zapf J. Schmid C. Froesch E.R. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates Acta Endocrinol. (Copenh.) 121 1989 753-758
25. Boulware S.D. Tamborlane W.V. Matthews L.S. Sherwin R.S. Diverse effects of insulin-like growth factor I on glucose lipid and amino acid metabolism Am. J. Physiol. 262 1992 E130-E133
26. Hizuka N. Takano K. Asakawa K. Sukegawa I. Fukuda I. Demura H. Iwashita M. Adachi T. Shizume K. Measurement of free form of insulin-like growth factor I in human plasma Growth Regul. 1 1991 51-55
27. P.D. Lee, D. Powell, B. Baker, F. Liu, G. Mathew, I. Levitsky, O.D. Gutierrez, R.L. Hintz, Characterization of a direct, non-extraction immunoradiometric assay for free IGF-I, Proc. 76th Ann. Meeting Endocrine Soc. 1994, Abstract 939
28. Weeke J. Boye N. Ørskov H. Ultrafiltration method for direct radioimmunoassay measurement of free thyroxine and free tri-iodothyronine in serum Scand. J. Clin. Lab. Invest. 46 1986 381-389
29. Ekins R. Measurement of free hormone in blood Endocr. Rev. 11 1990 5-46
30. Frystyk J. Dinesen B. Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II Growth Regul. 5 1995 169-176
31. Baxter R.C. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrisic bioactivities Am. J. Physiol. 278 2000 E967-E976
32. Lee D.Y. Park S.K. Yorgin P.D. Cohen P. Youngman O. Rosenfeld R.G. Alteration in insulin-like growth factor binding proteins (IGFBPs) and IGFBP-3 protease activity in serum and urine from acute and chronic renal failure J. Clin. Endocrinol. Metab. 79 1994 1376-1382
33. Frystyk J. Ivarsen P. Skjærbæk C. Flyvbjerg A. Pedersen E.B. Ørskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure Kidney Int. 56 1999 2076-2084
34. Frystyk J. Ivarsen P. Støving R.K. Dall R. Bek T. Hagen C. Ørskov H. Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay Growth Horm. IGF Res. 11 2001 117-127
35. Juul A. Holm K. Kastrup K.W. Pedersen S.A. Michaelsen K.F. Scheike T. Rasmussen S. Müller J. Skakkebæk N.E. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency J. Clin. Endocrinol. Metab. 82 1997 2497-2502
36. Juul A. Flyvbjerg A. Frystyk J. Müller J. Skakkebæk N.E. Serum concentrations of free and total insulin-like growth factor-I IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty Clin. Endocrinol. (Oxf.) 44 1996 515-523
37. Shalet S.M. Toogood A. Rahim A. Brennan B.M. The diagnosis of growth hormone deficiency in children and adults Endocr. Rev. 19 1998 203-223
38. Patel Y.C. Ezzat S. Chik C.L. Rorstad O.P. Serri O. Ur E. Wilkins G.E. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective Clin. Invest. Med. 23 2000 172-187
39. Strasburger C.J. Bidlingmaier M. Wu Z. Morrison K.M. Normal values of insulin-like growth factor I and their clinical utility in adults Horm. Res. 55 Suppl. 2 2001 100-105
40. Peacey S.R. Shalet S.M. Insulin-like growth factor I measurement in diagnosis and management of acromegaly Ann. Clin. Biochem. 38 2001 297-303
41. Hoffman D.M. O'Sullivan A.J. Baxter R.C. Ho K.K. Diagnosis of growth-hormone deficiency in adults Lancet 343 1994 1064-1068
42. Fukuda I. Hizuka N. Itoh E. Yasumoto K. Ishikawa Y. Murakami Y. Sata A. Takano K. Acid-labile subunit in growth hormone excess and deficiency in adults: evaluation of its diagnostic value in comparison with insulin-like growth factor (IGF)-I and IGF-binding protein-3 Endocr. J. 49 2002 379-386
43. Feld S. Hirschberg R. Growth hormone the insulin-like growth factor system, and the kidney Endocr. Rev. 17 1996 423-480
44. Scacchi M. Pincelli A.I. Cavagnini F. Growth hormone in obesity Int. J. Obes. Relat. Metab. Disord. 23 1999 260-271
45. Bereket A. Lang C.H. Wilson T.A. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus Horm. Metab. Res. 31 1999 172-181
46. Giustina A. Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human Endocr. Rev. 19 1998 717-797
47. Kojima M. Hosoda H. Matsuo H. Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor Trends Endocrinol. Metab. 12 2001 118-122
48. Muccioli G. Tschöp M. Papotti M. Deghenghi R. Heiman M. Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity Eur. J. Phar. 440 2002 235-254
49. Baxter R.C. Circulating levels and molecular distribution of the acid-labile (alpha) subunit of the high molecular weight insulin-like growth factor-binding protein complex J. Clin. Endocrinol. Metab. 70 1990 1347-1353
50. Blum W.F. Albertsson-Wikland K. Rosberg S. Ranke M.B. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion J. Clin. Endocrinol. Metab. 76 1993 1610-1616
51. Juul A. Møller S. Mosfeldt-Laursen E. Rasmussen M.H. Scheike T. Pedersen S.A. Kastrup K.W. Yu H. Mistry J. Rasmussen S. Müller J. Henriksen J. Skakkebæk N.E. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release diurnal variation, circulating concentrations in healthy subjects and diagnostic use in patients with growth hormone deficiency J. Clin. Endocrinol. Metab. 83 1998 4408-4415
52. Boisclair Y.R. Rhoads R.P. Ueki I. Wang J. Ooi G.T. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system J. Endocrinol. 170 2001 63-70
53. Frystyk J. Vestbo E. Skjærbæk C. Mogensen C.E. Ørskov H. Free insulin-like growth factors in human obesity Metabolism 44 Suppl. 4 1995 37-44
54. Janssen J.A. Stolk R.P. Pols H.A. Grobbee D.E. de J.F. Lamberts S.W. Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels Clin. Endocrinol. (Oxf.) 48 1998 471-478
55. Kawai N. Kanzaki S. Takano-Watou S. Tada C. Yamanaka Y. Miyata T. Oka M. Seino Y. Serum free insulin-like growth factor I (IGF-I) total IGF-I, and IGF- binding protein-3 concentrations in normal children and children with hormone deficiency J. Clin. Endocrinol. Metab. 84 1999 82-89
56. Boni Schnetzler M. Schmid C. Meier P.J. Froesch E.R. Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes Am. J. Physiol. 260 1991 E846-E851
57. Baxter R.C. Bryson J.M. Turtle J.R. The effect of fasting on liver receptors for prolactin and growth hormone Metabolism 30 1981 1086-1090
58. Leung K.C. Doyle N. Ballesteros M. Waters M.J. Ho K.K. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation J. Clin. Endocrinol. Metab. 85 2000 4712-4720
59. Wurzburger M.I. Prelevic G.M. Sonksen P.H. Balint Peric L.A. Wheeler M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes J. Clin. Endocrinol. Metab. 77 1993 267-272
60. Dominici F.P. Turyn D. Growth hormone-induced alterations in the insulin-signaling system Exp. Biol. Med. (Maywood) 227 2002 149-157
61. Cox G.N. McDermott M.J. Merkel E. Stroh C.A. Ko S.C. Squires C.H. Gleason T.M. Russell D. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats Endocrinology 135 1994 1913-1920
62. Wolf E. Lahm H. Wu M. Wanke R. Hoeflich A. Effects of IGFBP-2 overexpression in vitro and in vivo Pediatr. Nephrol. 14 2000 572-578
63. Frystyk J. Skjærbæk C. Vestbo E. Fisker S. Ørskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes Diabetes Metab. Res. Rev. 15 1999 314-322
64. Frystyk J. Delhanty P.J. Skjærbæk C. Baxter R.C. Changes in the circulating IGF system during short-term fasting and refeeding in rats Am. J. Physiol. 277 1999 E245-E252
65. Frystyk J. Højlund K. Rasmussen K.N. Jørgensen S.P. Wildner-Christensen M. Ørskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of insulin-like growth factor-I (IGF-I) and IGF-binding protein-1 in human serum J. Clin. Endocrinol. Metab. 84 2002 2324-2328
66. Pao C.I. Farmer P.K. Begovic S. Villafuerte B.C. Wu G.J. Robertson D.G. Phillips L.S. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by hormones and provision of amino acids in rat hepatocytes Mol. Endocrinol. 7 1993 1561-1568
67. Lee P.D. Giudice L.C. Conover C.A. Powell D.R. Insulin-like growth factor binding protein-1: recent findings and new directions Proc. Soc. Exp. Biol. Med. 216 1997 319-357
68. Ooi G.T. Tseng L.Y. Rechler M.M. Post-transcriptional regulation of insulin-like growth factor binding protein-2 mRNA in diabetic rat liver Biochem. Biophys. Res. Commun. 189 1992 1031-1037
69. Conover C.A. Lee P.D. Kanaley J.A. Clarkson J.T. Jensen M.D. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans J. Clin. Endocrinol. Metab. 74 1992 1355-1360
70. Brismar K. Fernqvist Forbes E. Wahren J. Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1) IGFBP-3 and IGF-I in insulin-dependent diabetes J. Clin. Endocrinol. Metab. 79 1994 872-878
71. Boni-Schnetzler M. Schmid C. Mary J.L. Zimmerli B. Meier P.J. Zapf J. Schwander J. Froesch E.R. Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes Mol. Endocrinol. 4 1990 1320-1326
72. Attia N. Caprio S. Jones T.W. Heptulla R. Holcombe J. Silver D. Sherwin R.S. Tamborlane W.V. Changes in free insulin-like growth factor-I and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes J. Clin. Endocrinol. Metab. 84 1999 2324-2328
73. Clemmons D.R. Snyder D.K. Busby W.H.J. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects J. Clin. Endocrinol. Metab. 73 1991 727-733
74. Lee P.D. Durham S.K. Martinez V. Vasconez O. Powell D.R. Guevara-Aguirre J. Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone J. Clin. Endocrinol. Metab. 82 1997 2266-2274
75. Frystyk J. Grøfte T. Skjærbæk C. Ørskov H. The effect of oral glucose on serum free insulin-like growth factor-I and -II in healthy adults J. Clin. Endocrinol. Metab. 82 1997 312-3127
76. Frystyk J. Hussain M. Skjærbæk C. Schmitz O. Christiansen J.S. Froesch E.R. Ørskov H. Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline Am. J. Physiol. 273 1997 E507-E513
77. Van Doorn J. Ringeling A.M. Shmueli S.S. Kuijpers M.C. Hokken-Koelega A.C. Buul-Offers S.C. Jansen M. Circulating levels of human insulin-like growth factor binding protein-6 (IGFBP-6) in health and disease as determined by radioimmunoassay Clin Endocrinol. (Oxf.) 50 1999 601-609
78. Baxter R.C. Meka S. Firth S.M. Molecular distribution of IGF binding protein-5 in human serum J. Clin. Endocrinol. Metab. 87 2002 271-276
79. Van Doorn J. Cornelissen A.J. Buul-Offers S.C. Plasma levels of insulin-like growth factor binding protein-4 (IGFBP-4) under normal and pathological conditions Clin. Endocrinol. (Oxf.) 54 2001 655-664
80. Kim E.J. Schaffer B.S. Kang Y.H. MacDonald R.G. Park J.H. Decreased production of insulin-like growth factor-binding protein (IGFBP)-6 by transfection of colon cancer cells with an antisense IGFBP-6 cDNA construct leads to stimulation of cell proliferation J. Gastroenterol. Hepatol. 17 2002 563-570
81. Jehle P.M. Ostertag A. Schulten K. Schulz W. Jehle D.R. Stracke S. Fiedler R. Deuber H.J. Keller F. Boehm B.O. Baylink D.J. Mohan S. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy Kidney Int. 57 2000 423-436
82. Jehle P.M. Schulten K. Schulz W. Jehle D.R. Stracke S. Manfras B. Boehm B.O. Baylink D.J. Mohan S. Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients Eur.J. Intern. Med. 14 2003 32-38
83. Twigg S.M. Baxter R.C. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit J. Biol. Chem. 273 1998 6074-6079
84. Juul A. Main K. Blum W.F. Lindholm J. Ranke M.B. Skakkebæk N.E. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients Clin. Endocrinol. (Oxf.) 41 1994 85-93
85. Hasegawa Y. Hasegawa T. Fujii K. Konii H. Anzo M. Aso T. Koto S. Takada M. Tsuchiya Y. High ratios of free to total insulin-like growth factor-I in early infancy J. Clin. Endocrinol. Metab. 82 1997 156-158
86. Janssen J.A. Jacobs M.L. Derkx F.H. Weber R.F. van der Lely A.J. Lamberts S.W. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1) and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus J. Clin. Endocrinol. Metab. 82 1997 2809-2815
87. Yu H. Mistry J. Nicar M.J. Khosravi M.J. Diamandis A. Van Doorn J. Juul A. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation J. Clin. Lab. Anal. 13 1999 166-172
88. Iranmanesh A. Lizarralde G. Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men J. Clin. Endocrinol. Metab. 73 1991 1081-1088
89. Flegal K.M. Carroll M.D. Kuczmarski R.J. Johnson C.L. Overweight and obesity in the United States: prevalence and trends, 1960-1994 Int. J. Obes. Relat. Metab. Disord. 22 1998 39-47
90. Jørgensen J.O. Hansen T.K. Conceicao F.L. Christensen J.J. Vahl N. Christiansen J.S. Short-term tools to measure responsiveness to growth hormone replacement Horm. Res. 55 Suppl. 2 2001 40-43
91. Carroll P.V. Christ E.R. Bengtsson B.A. Carlsson L. Christiansen J.S. Clemmons D. Hintz R. Ho K. Laron Z. Sizonenko P. Sönksen P.H. Tanaka T. Thorner M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee J. Clin. Endocrinol. Metab. 83 1998 382-395
92. Sizonenko P.C. Clayton P.E. Cohen P. Hintz R.L. Tanaka T. Laron Z. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: diagnosis of growth hormone deficiency Growth Horm. IGF Res. 11 2001 137-165
93. Growth Hormone Research Society, Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement for the GH Research Society, J. Pediatr. Endocrinol. Metab. 14 (2001) 377-382
94. Growth Hormone Research Society, Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the GH Research Society workshop on adult growth hormone deficiency, J. Clin. Endocrinol. Metab. 83 (1998) 379-381
95. Hoeck H.C. Vestergaard P. Jakobsen P.E. Falhof J. Laurberg P. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues J. Clin. Endocrinol. Metab. 85 2000 1467-1472
96. Ghigo E. Bellone J. Aimaretti G. Bellone S. Loche S. Cappa M. Bartolotta E. Dammacco F. Camanni F. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children J. Clin. Endocrinol. Metab. 81 1996 3323-3327
97. Granada M.L. Sanmarti A. Lucas A. Salinas I. Carrascosa A. Foz M. Audi L. Assay-dependent results of immunoassayable spontaneous 24-h growth hormone secretion in short children Acta Paediatr. Scand. Suppl. 370 1990 63-70
98. de Boer H. Blok G.J. van der Veen E.A. Clinical aspects of growth hormone deficiency in adults Endocr. Rev. 16 1995 63-86
99. Marzullo P. Di Somma C. Pratt K.L. Khosravi J. Diamandis A. Lombardi G. Colao A. Rosenfeld R.G. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults J. Clin. Endocrinol. Metab. 86 2001 3001-3008
100. Smith W.J. Nam T.J. Underwood L.E. Busby W.H. Celnicker A. Clemmons D.R. Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children J. Clin. Endocrinol. Metab. 77 1993 1294-1299
101. Hilding A. Brismar K. Degerblad M. Thoren M. Hall K. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects J. Clin. Endocrinol. Metab. 80 1995 2646-2652
102. Skjærbæk C. Kaal A. Møller J. Vahl N. Weeke J. Ørskov H. Flyvbjerg A. No effect of growth hormone on serum insulin-like growth factor binding protein-3 proteolysis J. Clin. Endocrinol. Metab. 83 1998 120-1210
103. Yamada M. Hasegawa T. Hasegawa Y. Absence of proteolysis of insulin-like growth factor binding protein-3 in serum from patients with growth hormone deficiency Endocr. J. 46 1999 717-722
104. Baxter R.C. Martin J.L. Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma J. Clin. Invest. 78 1986 1504-1512
105. Rosenfeld R.G. Wilson D.M. Lee P.D. Hintz R.L. Insulin-like growth factors I and II in evaluation of growth retardation J. Pediatr. 109 1986 428-433
106. Fernholm R. Bramnert M. Hagg E. Hilding A. Baylink D.J. Mohan S. Thoren M. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease J. Clin. Endocrinol. Metab. 85 2000 4104-4112
107. Skjærbæk C. Frystyk J. Møller J. Christiansen J.S. Ørskov H. Free and total insulin-like growth factors and insulin-like growth factor binding proteins during 14 days of growth hormone administration in healthy adults Eur. J. Endocrinol. 135 1996 672-677
108. Murphy L.J. Seneviratne C. Moreira P. Reid R.E. Enhanced expression of insulin-like growth factor-binding protein-1 in the fasted rat: the effects of insulin and growth hormone administration Endocrinology 128 1991 689-696
109. Nørrelund H. Fisker S. Vahl N. Børglum J. Richelsen B. Christiansen J.S. Jørgensen J.O. Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults Growth Horm. IGF Res. 9 1999 52-60
110. Rosenfalck A.M. Maghsoudi S. Fisker S. Jørgensen J.O. Christiansen J.S. Hilsted J. Volund A.A. Madsbad S. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults J. Clin. Endocrinol. Metab. 85 2000 4173-4181
111. Yuen K. Ong K. Husbands S. Chatelain P. Fryklund L. Gluckman P. Ranke M. Cook D. Rosenfeld R. Wass J. Dunger D. The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults J. Clin. Endocrinol. Metab. 87 2002 1989-1995
112. Giustina A. Barkan A. Casanueva F.F. Cavagnini F. Frohman L. Ho K. Veldhuis J. Wass J. Von Werder K. Melmed S. Criteria for cure of acromegaly: a consensus statement J. Clin. Endocrinol. Metab. 85 2000 526-529
113. Okada S. Chen W.Y. Wiehl P. Kelder B. Goodman H.M. Guller S. Sonenberg M. Kopchick J.J. A growth hormone (GH) analog can antagonize the ability of native GH to promote differentiation of 3T3-F442A preadipocytes and stimulate insulin-like and lipolytic activities in primary rat adipocytes Endocrinology 130 1992 2284-2290
114. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease Diabetologia 43 2000 1205-1223
115. Kopchick J.J. Parkinson C. Stevens E.C. Trainer P.J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly Endocr. Rev. 23 2002 623-646
116. Melmed S. Casanueva F.F. Cavagnini F. Chanson P. Frohman L. Grossman A. Ho K. Kleinberg D. Lamberts S. Laws E. Lombardi G. Vance M.L. Werder K.V. Wass J. Giustina A. Guidelines for acromegaly management J. Clin. Endocrinol. Metab. 87 2002 4054-4058
117. Freda P.U. Post K.D. Powell J.S. Wardlaw S.L. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly J. Clin. Endocrinol. Metab. 83 1998 380-3816
118. Barkan A.L. Beitins I.Z. Kelch R.P. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion J. Clin. Endocrinol. Metab. 67 1988 69-73
119. Bates A.S. Evans A.J. Jones P. Clayton R.N. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion Clin. Endocrinol. (Oxf.) 42 1995 417-423
120. Dobrashian R.D. O'Halloran D.J. Hunt A. Beardwell C.G. Shalet S.M. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly Clin. Endocrinol. (Oxf.) 38 1993 589-593
121. van der Lely A.J. de H.W. Janssen J.A. Lamberts S.W. Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis J. Endocrinol. 155 Suppl. 1 1997 S9-S13
122. Arosio M. Garrone S. Bruzzi P. Faglia G. Minuto F. Barreca A. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3 J. Clin. Endocrinol. Metab. 86 2001 1091-1098
123. Sneppen S.B. Lange M. Pedersen L.M. Kristensen L.L. Main K.M. Juul A. Skakkebæk N.E. Feldt-Rasmussen U. Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly Growth Horm. IGF Res. 11 2001 384-391
124. Kaal A. Frystyk J. Skjærbæk C. Nielsen S. Jørgensen J.O.L. Bruns C. Marbach P. Lancranjan I. Weeke J. Ørskov H. Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs), free IGFs, and IGF-binding proteins in acromegalic patients Metabolism 44 Suppl. 1 1995 6-14
125. Ezzat S. Ren S.G. Braunstein G.D. Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action J. Clin. Endocrinol. Metab. 75 1992 1459-1463
126. Flyvbjerg A. Schuller A.G. van Neck J.W. Groffen C. Ørskov H. Drop S.L. Stimulation of hepatic insulin-like growth factor-binding protein-1 and -3 gene expression by octreotide in rats J. Endocrinol. 147 1995 545-551
127. Wolthers T. Grøfte T. Flyvbjerg A. Frystyk J. Vilstrup H. Ørskov H. Foegh M. Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide J. Clin. Endocrinol. Metab. 78 1994 141-144
128. Trainer P.J. Drake W.M. Katznelson L. Freda P.U. Herman-Bonert V. van der Lely A.J. Dimaraki E.V. Stewart P.M. Friend K.E. Vance M.L. Besser G.M. Scarlett J.A. Thorner M.O. Parkinson C. Klibanski A. Powell J.S. Barkan A.L. Sheppard M.C. Malsonado M. Rose D.R. Clemmons D.R. Johannsson G. Bengtsson B.A. Stavrou S. Kleinberg D.L. Cook D.M. Phillips L.S. Bidlingmaier M. Strasburger C.J. Hackett S. Zib K. Bennett W.F. Davis R.J. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant N. Engl. J. Med. 342 2000 1171-1177
129. van der Lely A.J. Hutson R.K. Trainer P.J. Besser G.M. Barkan A.L. Katznelson L. Klibanski A. Herman-Bonert V. Melmed S. Vance M.L. Freda P.U. Stewart P.M. Friend K.E. Clemmons D.R. Johannsson G. Stavrou S. Cook D.M. Phillips L.S. Strasburger C.J. Hackett S. Zib K.A. Davis R.J. Scarlett J.A. Thorner M.O. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist Lancet 358 2001 1754-1759
130. Parkinson C. Drake W.M. Roberts M.E. Meeran K. Besser G.M. Trainer P.J. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal J. Clin. Endocrinol. Metab. 87 2002 1797-1804
131. Rose D.R. Clemmons D.R. Growth hormone receptor antagonist improves insulin resistance in acromegaly Growth Horm. IGF Res. 12 2002 418-424
132. Vanderschueren-Lodeweyckx M. The effect of simple obesity on growth and growth hormone Horm. Res. 40 1993 23-30
133. Rasmussen M.H. Frystyk J. Andersen T. Breum L. Christiansen J.S. Hilsted J. The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone Metabolism 43 1994 315-319
134. Kjeldsen H. Hansen A.P. Lundbæk K. Twenty-four-hour serum growth hormone levels in maturity-onset diabetics Diabetes 24 1975 977-982
135. Christensen S.E. Hansen A.P. Ørskov H. Lundbæk K. Twenty-four-hour somatostatin infusions in normals, juvenile diabetics, and maturity-onset diabetics Metabolism 27 1978 1427-1431
136. Giustina A. Wehrenberg W.B. Growth hormone neuroregulation in diabetes mellitus Trends Endocrinol. Metab. 5 1994 73-78
137. Levy C.J. Kinsley B.T. Bajaj M. Simonson D.C. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM Diabetes Care 21 1998 1330-1338
138. Spyer G. Hattersley A.T. MacDonald I.A. Amiel S. MacLeod K.M. Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes Lancet 356 2000 1970-1974
139. Simpson H.L. Umpleby A.M. Russell-Jones D.L. Insulin-like growth factor-I and diabetes. A review Growth Horm. IGF Res. 8 1998 83-95
140. Bluher M. Kratzsch J. Paschke R. Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance Diabetes Care 24 2001 328-334
141. Attia N. Tamborlane W.V. Heptulla R. Maggs D. Grozman A. Sherwin R.S. Caprio S. The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity J. Clin. Endocrinol. Metab. 83 1998 1467-1471
142. Nam S.Y. Lee E.J. Kim K.R. Cha B.S. Song Y.D. Lim S.K. Lee H.C. Huh K.B. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone Int. J. Obes. Relat. Metab. Disord. 21 1997 355-359
143. Argente J. Caballo N. Barrios V. Pozo J. Munoz M.T. Chowen J.A. Hernandez M. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in prepubertal children
144. Park M.J. Kim H.S. Kang J.H. Kim D.H. Chung C.Y. Serum levels of insulin-like growth factor (IGF)-I, free IGF-I, IGF binding protein (IGFBP)-1, IGFBP-3 and insulin in obese children J. Pediatr. Endocrinol. Metab. 12 1999 139-144
145. Matthews D.R. Hosker J.P. Rudenski A.S. Naylor B.A. Treacher D.F. Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412-419
146. Albareda M. Rodriguez-Espinosa J. Murugo M. de Leiva A. Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test Diabetologia 43 2000 1507-1511
147. Heald A.H. Cruickshank J.K. Riste L.K. Cade J.E. Anderson S. Greenhalgh A. Sampayo J. Taylor W. Fraser W. White A. Gibson J.M. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations Diabetologia 44 2001 333-339
148. Feldmann B. Jehle P.M. Mohan S. Lang G.E. Lang G.K. Brueckel J. Boehm B.O. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins Growth Horm. IGF Res. 10 2000 53-59
149. Frystyk J. Skjærbæk C. Zapf J. Ørskov H. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia Diabetologia 41 1998 589-594
150. Skjærbæk C. Frystyk J. Kaal A. Laursen T. Møller J. Weeke J. Jørgensen J.O. Sandahl C.J. Ørskov H. Circadian variation in serum free and total insulin-like growth factor (IGF)-I and IGF-II in untreated and treated acromegaly and growth hormone deficiency Clin. Endocrinol. (Oxf.) 52 2000 25-33
151. Wabitsch M. Heinze E. Debatin K.M. Blum W.F. IGF-I and IGFBP-3-expression in cultured human preadipocytes and adipocytes Horm. Metab. Res. 32 2000 555-559
152. Weber M.M. Melmed S. Rosenbloom J. Yamasaki H. Prager D. Rat somatotroph insulin-like growth factor-II (IGF-II) signaling: role of the IGF-I receptor Endocrinology 131 1992 2147-2153
153. Maccario M. Tassone F. Gauna C. Oleandri S.E. Aimaretti G. Procopio M. Grottoli S. Pflaum C.D. Strasburger C.J. Ghigo E. Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH Eur. J. Endocrinol. 144 2001 251-256
154. Barnard R. Waters M.J. The serum growth hormone binding protein: pregnant with possibilities J. Endocrinol. 153 1997 1-14
155. Amit T. Youdim M.B. Hochberg Z. Clinical review 112: does serum growth hormone (GH) binding protein reflect human GH receptor function? J. Clin. Endocrinol. Metab. 85 2000 927-932
156. Johansen K. Hansen Aa.P. Diurnal serum growth hormone levels in poorly and well controlled juvenile diabetics Diabetes 20 1971 239-245
157. Møller N. The role of growth hormone in the regulation of human fuel metabolism in: Flyvbjerg A. Ørskov H. Alberti K.G.M.M. (Eds.) Growth Hormone and Insulin-like Growth Factor I in Human and Experimental Diabetes 1993 77-108 Wiley New York
158. Shishko P.I. Dreval A.V. Abugova I.A. Zajarny I.U. Goncharov V.C. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion Diabetes Res. Clin. Pract. 25 1994 1-12
159. Bereket A. Lang C.H. Blethen S.L. Ng L.C. Wilson T.A. Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children Clin. Endocrinol. (Oxf.) 45 1996 321-326
160. Krsek M. Prazny M. Skrha J. Justova V. Lacinova Z. Haas T. The relationship between the IGF-I system and its binding proteins and microvascular reactivity in Type 1 diabetes mellitus Physiol. Res. 51 2002 379-385
161. Frystyk J. Bek T. Flyvbjerg A. Skjærbæk C. Ørskov H. The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients Diabetes Med. 20 2003 269-276
162. Wacharasindhu S. Srivuthana S. Aroonparkmongkol S. Insulin-like growth factors and their binding proteins in children with IDDM J. Med. Assoc. Thai. 85 2002 41-52
163. Flyvbjerg A. Thorlacius-Ussing O. Næraa R. Ingerslev J. Ørskov H. Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats Diabetologia 31 1988 310-314
164. Sharp P.S. Diabetic retinopathy: an analysis of the possible pathogenic roles of growth hormone and insulin-like growth factor I in: Flyvbjerg A. Ørskov H. Alberti K.G.M.M. (Eds.) Growth Hormone and Insulin-like Growth Factor I in Human and Experimental Diabetes 1993 203-228 Wiley New York
165. Merimee T.J. Zapf J. Froesch E.R. Insulin-like growth factors. Studies in diabetics with and without retinopathy N. Engl. J. Med. 309 1983 527-530
166. Hyer S.L. Sharp P.S. Brooks R.A. Burrin J.M. Kohner E.M. Serum IGF-I concentration in diabetic retinopathy Diabetes Med. 5 1988 356-360
167. Wang Q. Dills D.G. Klein R. Klein B.E. Moss S.E. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 44 1995 161-164
168. Chantelau E. Eggert H. Seppel T. Schonau E. Althaus C. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome Br. J. Ophthalmol. 81 1997 169-170
169. Hyer S.L. Sharp P.S. Sleightholm M. Burrin J.M. Kohner E.M. Progression of diabetic retinopathy and changes in serum insulin-like growth factor I (IGF I) during continuous subcutaneous insulin infusion (CSII) Horm. Metab. Res. 21 1989 18-22
170. Møller N. Ørskov H. Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications? Lancet 350 1997 1188-1189
171. Smith L.E. Shen W. Perruzzi C. Soker S. Kinose F. Xu X. Robinson G. Driver S. Bischoff J. Zhang B. Schaeffer J.M. Senger D.R. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor Nat. Med. 5 1999 1390-1395
172. Amin R. Schultz C. Ong K. Frystyk J. Dalton R.N. Perry L. Ørskov H. Dunger D.B. Low IGF-I and Elevated Testosterone During Puberty in Subjects With Type 1 Diabetes Developing Microalbuminuria in Comparison to Normoalbuminuric Control Subjects: The Oxford Regional Prospective Study Diabetes Care 26 2003 1456-1461
173. Tönshoff B. Blum W.F. Mehls O. Derangements of the somatotropic hormone axis in chronic renal failure Kidney Int. Suppl. 58 1997 S106-S113
174. Schwalbe S.L. Betts P.R. Rayner P.H. Rudd B.T. Somatomedin in growth disorders and chronic renal insufficiency in children Br. Med. J. 1 1977 679-682
175. Phillips L.S. Fusco A.C. Unterman T.G. del Greco F. Somatomedin inhibitor in uremia J. Clin. Endocrinol. Metab. 59 1984 764-772
176. Blum W.F. Ranke M.B. Kietzmann K. Tönshoff B. Mehls O. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia Pediatr. Nephrol. 5 1991 539-544
177. Powell D.R. Durham S.K. Brewer E.D. Frane J.W. Watkins S.L. Hogg R.J. Mohan S. Effects of chronic renal failure and growth hormone on serum levels of insulin-like growth factor-binding protein-4 (IGFBP-4) and IGFBP-5 in children: a report of the Southwest Pediatric Nephrology Study Group J. Clin. Endocrinol. Metab. 84 1999 596-601
178. Powell D.R. Liu F. Baker B. Lee P.D. Belsha C.W. Brewer E.D. Hintz R.L. Characterization of insulin-like growth factor binding protein-3 in chronic renal failure serum Pediatr. Res. 33 1993 136-143
179. Lalou C. Lassarre C. Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin Endocrinology 137 1996 3206-3212
180. Tönshoff B. Blum W.F. Wingen A. Mehls O. Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2 and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate J. Clin. Endocrinol. Metab. 80 1995 2684-2691
181. Schmitz O. Alberti K.G. Christensen N.J. Hasling C. Hjøllund E. Beck-Nielsen H. Ørskov H. Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique Metabolism 34 1985 465-473
182. Powell D.R. Liu F. Baker B.K. Hintz R.L. Lee P.D. Durham S.K. Brewer E.D. Frane J.W. Watkins S.L. Hogg R.J. Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group Kidney Int. 51 1997 1970-1979
183. Haffner D. Blum W.F. Heinrich U. Mehls O. Tönshoff B. Impaired postprandial regulation of insulin-like growth factor binding protein-1 in children with chronic renal failure J. Clin. Endocrinol. Metab. 82 1997 2832-2835
184. Rabkin R. Fervenza F.C. Maidment H. Ike J. Hintz R. Liu F. Bloedow D.C. Hoffman A.R. Gesundheit N. Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failure Kidney Int. 49 1996 1134-1140
185. Bereket A. Lang C.H. Blethen S.L. Kaskel F.J. Stewart C. Wilson T.A. Growth hormone treatment in growth retarded children with end stage renal failure: effect on free/dissociable IGF-I levels J. Pediatr. Endocrinol. Metab. 10 1997 197-202
186. Wagner M.S. Stracke S. Jehle P.M. Keller F. Zellner D. Baylink D.J. Mohan S. Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts Nephron 84 2000 158-166
187. Hartman M.L. Veldhuis J.D. Johnson M.L. Lee M.M. Alberti K.G. Samojlik E. Thorner M.O. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men J. Clin. Endocrinol. Metab. 74 1992 757-765
188. Cotterill A.M. Holly J.M. Wass J.A. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting Clin. Endocrinol. (Oxf.) 39 1993 357-362
189. Bang P. Brismar K. Rosenfeld R.G. Hall K. Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with noninsulin-dependent diabetes mellitus versus healthy nonobese and obese subjects J. Clin. Endocrinol. Metab. 78 1994 960-967
190. Merimee T.J. Zapf J. Froesch E.R. Insulin-like growth factors in the fed and fasted states J. Clin. Endocrinol. Metab. 55 1982 999-1002
191. Muller A.F. Lamberts S.W. Janssen J.A. Hofland L.J. Koetsveld P.V. Bidlingmaier M. Strasburger C.J. Ghigo E. van der Lely A.J. Ghrelin drives GH secretion during fasting in man Eur. J. Endocrinol. 146 2002 203-207
192. Katz L.E. DeLeon D.D. Zhao H. Jawad A.F. Free and total insulin-like growth factor (IGF)-I levels decline during fasting: relationships with insulin and IGF-binding protein-1 J. Clin. Endocrinol. Metab. 87 2002 2978-2983
193. Davenport M.L. Svoboda M.E. Koerber K.L. Van Wyk J.J. Clemmons D.R. Underwood L.E. Serum concentrations of insulin-like growth factor II are not changed by short-term fasting and refeeding J. Clin. Endocrinol. Metab. 67 1988 1231-1236
194. Grottoli S. Gauna C. Tassone F. Aimaretti G. Corneli G. Wu Z. Strasburger C.J. Dieguez C. Casanueva F.F. Ghigo E. Maccario M. Both fasting-induced leptin reduction and GH increase are blunted in Cushing's syndrome and in simple obesity Clin. Endocrinol. (Oxf.) 58 2003 220-228
195. Maccario M. Aimaretti G. Grottoli S. Gauna C. Tassone F. Corneli G. Rossetto R. Wu Z. Strasburger C.J. Ghigo E. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency Int. J. Obes. Relat. Metab. Disord. 25 2001 1233-1239
196. Støving R.K. Hangaard J. Hagen C. Update on endocrine disturbances in anorexia nervosa J. Pediatr. Endocrinol. Metab. 14 2001 459-480
197. Argente J. Caballo N. Barrios V. Munoz M.T. Pozo J. Chowen J.A. Morande G. Hernandez M. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short- and long-term weight recuperation J. Clin. Endocrinol. Metab. 82 1997 2084-2092
198. Counts D.R. Gwirtsman H. Carlsson L.M. Lesem M. Cutler G.B.J. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins J. Clin. Endocrinol. Metab. 75 1992 762-767
199. Støving R.K. Flyvbjerg A. Frystyk J. Fisker S. Hangaard J. Hansen-Nord M. Hagen C. Low serum levels of free and total insulin-like growth factor I (IGF-I) in patients with anorexia nervosa are not associated with increased IGF- binding protein-3 proteolysis J. Clin. Endocrinol. Metab. 84 1999 1346-1350
200. Froesch E.R. Hussain M.A. Schmid C. Zapf J. Insulin-like growth factor I: physiology, metabolic effects and clinical uses Diabetes Metab. Rev. 12 1996 195-215
201. Acerini C.L. Dunger D.B. Insulin-like growth factor-I for the treatment of type 1 diabetes Diabetes Obes. Metab. 2 2000 335-343
202. Chapman I.M. Hartman M.L. Pieper K.S. Skiles E.H. Pezzoli S.S. Hintz R.L. Thorner M.O. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor-I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I J. Clin. Endocrinol. Metab. 83 1998 2836-2842
203. Blat C. Villaudy J. Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells J. Clin. Invest. 93 1994 2286-2290
204. Chernausek S.D. Smith C.E. Duffin K.L. Busby W.H. Wright G. Clemmons D.R. Proteolytic cleavage of insulin-like growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4 J. Biol. Chem. 270 1995 11377-11382
205. Imai Y. Busby W.H.J. Smith C.E. Clarke J.B. Garmong A.J. Horwitz G.D. Rees C. Clemmons D.R. Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture J. Clin. Invest. 100 1997 2596-2605
206. Suikkari A.M. Baxter R.C. Insulin-like growth factor-binding protein-3 is functionally normal in pregnancy serum J. Clin. Endocrinol. Metab. 74 1992 177-183
207. Cwyfan Hughes S.C. Cotterill A.M. Molloy A.R. Cassell T.B. Braude N. Hinds C.J. Wass J.A. Holly J.M. The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery J. Endocrinol. 135 1992 135-145
208. Bang P. Serum proteolysis of IGFBP-3 Prog. Growth Factor Res. 6 1995 285-292
209. Bang P. Brismar K. Rosenfeld R.G. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex J. Clin. Endocrinol. Metab. 78 1994 1119-1127
210. Bereket A. Lang C.H. Blethen S.L. Fan J. Frost R.A. Wilson T.A. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: a possible role for insulin in the regulation of IGFBP-3 protease activity J. Clin. Endocrinol. Metab. 80 1995 2282-2288
211. Lassarre C. Binoux M. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma Endocrinology 134 1994 1254-1262
212. Hasegawa T. Hasegawa Y. Takada M. Tsuchiya Y. The free form of insulin-like growth factor I increases in circulation during normal human pregnancy J. Clin. Endocrinol. Metab. 80 1995 3284-3286
213. Skjærbæk C. Frystyk J. Ørskov H. Kissmeyer-Nielsen P. Jensen M.B. Laurberg S. Møller N. Flyvbjerg A. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis J. Clin. Endocrinol. Metab. 83 1998 2445-2449
214. Baxter R.C. Skriver L. Altered ligand specificity of proteolysed insulin-like growth factor binding protein-3 Biochem. Biophys. Res. Commun. 196 1993 1267-1273
215. Baxter R.C. What is the significance of IGF-binding protein-3 proteolysis in the circulation? J Clin. Endocrinol. Metab. 86 2001 5087-5088
216. Baxter R.C. Suikkari A.M. Martin J.L. Characterization of the binding defect in insulin-like growth factor binding protein-3 from pregnancy serum Biochem. J. 294 1993 847-852
217. Guler H.P. Zapf J. Froesch E.R. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults N. Engl. J. Med. 317 1987 137-140
218. Holt R.I. Simpson H.L. Sonksen P.H. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis Diabetes Med. 20 2003 3-15
219. Di Cola G. Cool M.H. Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors J. Clin. Invest. 99 1997 2538-2544
220. Ørskov L. Møller N. Bak J.F. Pørksen N. Schmitz O. Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus Metabolism 45 1996 211-217
221. Hussain M.A. Schmitz O. Christiansen J.S. Zapf J. Froesch E.R. Metabolic effects of insulin-like growth factor-I in: Juul A. Jørgensen J.O.L. (Eds.) Growth Hormone in Adults, Physiological and Clinical Aspects 1996 91-106 Cambridge University Press Cambridge
222. Lee P.D. Conover C.A. Powell D.R. Regulation and function of insulin-like growth factor-binding protein-1 Proc. Soc. Exp. Biol. Med. 204 1993 4-29
223. Baxter R.C. Insulin-like growth factor binding proteins as glucoregulators Metabolism 44 1995 12-17
224. Lewitt M.S. Denyer G.S. Cooney G.J. Baxter R.C. Insulin-like growth factor-binding protein-1 modulates blood glucose levels Endocrinology 129 1991 2254-2256
225. Rajkumar K. Barron D. Lewitt M.S. Murphy L.J. Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice Endocrinology 136 1995 4029-4034
226. Rajkumar K. Dheen S.T. Murphy L.J. Hyperglycemia and impaired glucose tolerance in IGF binding protein-1 transgenic mice Am. J. Physiol. 270 1996 E565-E571
227. Rajkumar K. Krsek M. Dheen S.T. Murphy L.J. Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice J. Clin. Invest. 98 1996 1818-1825
228. Carlsson Skwirut C. Lake M. Hartmanis M. Hall K. Sara V.R. A comparison of the biological activity of the recombinant intact and truncated insulin-like growth factor 1 (IGF-1) Biochim. Biophys. Acta 1011 1989 192-197
229. Crossey P.A. Jones J.S. Miell J.P. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance Diabetes 49 2000 457-465
230. Mortensen D.L. Won W.B. Siu J. Reifsnyder D. Gironella M. Etcheverry T. Clark R.G. Insulin-like growth factor binding protein-1 induces insulin release in the rat Endocrinology 138 1997 2073-2080
231. Pørksen N. Hussain M.A. Bianda T.L. Nyholm B. Christiansen J.S. Butler P.C. Veldhuis J.D. Froesch E.R. Schmitz O. IGF-I inhibits burst mass of pulsatile insulin secretion at supraphysiological and low IGF-I infusion rates Am. J. Physiol. 272 1997 E352-E358
232. Dai Z. Xing Y. Boney C.M. Clemmons D.R. D'Ercole A.J. Human insulin-like growth factor-binding protein-1 (hIGFBP-1) in transgenic mice: characterization and insights into the regulation of IGFBP-1 expression Endocrinology 135 1994 1316-1327
233. Gay E. Seurin D. Babajko S. Doublier S. Cazillis M. Binoux M. Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: repercussions on reproduction, ante- and perinatal mortality and postnatal growth Endocrinology 138 1997 2937-2947
234. Westwood M. Gibson J.M. Davies A.J. Young R.T. White A. The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy J. Clin. Endocrinol. Metab. 79 1994 1735-1741
235. Sakai K. D'Ercole A.J. Murphy L.J. Clemmons D.R. Physiological differences in insulin-like growth factor binding protein-1 (IGFBP-1) phosphorylation in IGFBP-1 transgenic mice Diabetes 50 2001 32-38
236. Jones J.I. D'Ercole A.J. Camacho Hubner C. Clemmons D.R. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I Proc. Natl. Acad. Sci. USA 88 1991 7481-7485
237. Peterkofsky B. Gosiewska A. Wilson S. Kim Y.R. Phosphorylation of rat insulin-like growth factor binding protein-1 does not affect its biological properties Arch. Biochem. Biophys. 357 1998 101-110
238. Ohlsson C. Sjogren K. Jansson J.O. Isaksson O.G. The relative importance of endocrine versus autocrine/paracrine insulin-like growth factor-I in the regulation of body growth Pediatr. Nephrol. 14 2000 541-543
239. Silha J.V. Murphy L.J. Insights from insulin-like growth factor binding protein transgenic mice Endocrinology 143 2002 3711-3714
240. Yakar S. Liu J.L. Fernandez A.M. Wu Y. Schally A.V. Frystyk J. Chernausek S.D. Mejia W. Le Roith D. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity Diabetes 50 2001 1110-1118
241. Frystyk J. Grønbæk H. Skjærbæk C. Flyvbjerg A. Ørskov H. Baxter R.C. Developmental changes in serum levels of free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit in rats Endocrinology 139 1998 4286-4292
242. Bereket A. Wilson T.A. Blethen S.L. Fan J. Frost R.A. Gelato M.C. Lang C.H. Effect of short-term fasting on free/dissociable insulin-like growth factor-I concentrations in normal human serum. J. Clin. Endocrinol. Metab. 81 1996 4379-4384
243. Nyomba B.L. Berard L. Murphy L.J. Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity J. Clin. Endocrinol. Metab. 82 1997 2177-2181
244. Ricart W. Fernandez-Real J.M. No decrease in free IGF-I with increasing insulin in obesity-related insulin resistance Obes. Res. 9 2001 631-636
245. Yeoh S.I. Baxter R.C. Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma Acta Endocrinol. (Copenh.) 119 1988 465-473
246. Westwood M. Gibson J.M. White A. Purification and characterization of the insulin-like growth factor binding protein-1 isoform found in normal plasma Endocrinology 138 1997 1130-1136
247. Frystyk J. Nyholm B. Skjærbæk C. Baxter R.C. Schmitz O. Ørskov H. The circulating IGF-system and its relationship with 24-hour glucose regulation and insulin sensitivity in healthy subjects Clin. Endocrinol. (Oxf.) 58 2003 777-784
248. Baxter R.C. Cowell C.T. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma J. Clin. Endocrinol. Metab. 65 1987 432-440
249. Heuck C. Skjærbæk C. Ørskov H. Wolthers O.D. Circadian variation in serum free ultrafiltrable insulin-like growth factor I concentrations in healthy children Pediatr. Res. 45 1999 733-736
250. Frystyk J. Role of IGFBP-1 in glucose regulation Acta Paediatr. 89 2000 1025-1031
251. Batch J.A. Baxter R.C. Werther G. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes J. Clin. Endocrinol. Metab. 73 1991 964-968
252. Cotterill A.M. Daly F. Holly J.M. Hughes S.C. Camacho Hubner C. Abdulla A.F. Gale E.A. Savage M.O. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1 Clin. Endocrinol. (Oxf.) 43 1995 567-574
253. Kobayashi K. Amemiya S. Sawanobori E. Higashida K. Ishihara T. Kobayashi K. Kato K. Nakazawa S. Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM Diabetes Care 20 1997 1442-1447
254. Kobayashi K. Kobayashi K. Mochizuki M. Matsushita K. Sawanobori E. Ishihara T. Higashida K. Amemiya S. A role of free insulin-like growth factor-I in dawn phenomenon in children and adolescents with type 1 diabetes mellitus Endocr. J. 47 Suppl. 2000 S91-S93
255. Frystyk J. Hussain M. Skjærbæk C. Pørksen N. Froesch E.R. Ørskov H. The pharmacokinetics of free insulin-like growth factor-I in healthy subjects Growth Horm. IGF Res. 9 1999 150-156
256. Efstratiadis A. Genetics of mouse growth Int. J. Dev. Biol. 42 1998 955-976
257. Lamothe B. Baudry A. Desbois P. Lamotte L. Bucchini D. De Meyts P. Joshi R.L. Genetic engineering in mice: impact on insulin signalling and action Biochem. J. 335 1998 193-204
258. Schneider M.R. Lahm H. Wu M. Hoeflich A. Wolf E. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins FASEB J. 14 2000 629-640
259. Nakae J. Kido Y. Accili D. Distinct and overlapping functions of insulin and IGF-I receptors Endocr. Rev. 22 2001 818-835
260. D'Ercole A.J. Ye P. O'Kusky J.R. Mutant mouse models of insulin-like growth factor actions in the central nervous system Neuropeptides 36 2002 209-220
261. Accili D. Drago J. Lee E.J. Johnson M.D. Cool M.H. Salvatore P. Asico L.D. Jose P.A. Taylor S.I. Westphal H. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene Nat. Genet. 12 1996 106-109
262. Mathews L.S. Hammer R.E. Behringer R.R. D'Ercole A.J. Bell G.I. Brinster R.L. Palmiter R.D. Growth enhancement of transgenic mice expressing human insulin-like growth factor I Endocrinology 123 1988 2827-2833
263. Behringer R.R. Lewin T.M. Quaife C.J. Palmiter R.D. Brinster R.L. D'Ercole A.J. Expression of insulin-like growth factor I stimulates normal somatic growth in growth hormone-deficient transgenic mice Endocrinology 127 1990 1033-1040
264. D'Ercole A.J. Expression of insulin-like growth factor-I in transgenic mice Ann.N.Y. Acad. Sci. 692 1993 149-160
265. Withers D.J. Burks D.J. Towery H.H. Altamuro S.L. Flint C.L. White M.F. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling Nat. Genet. 23 1999 32-40
266. Baker J. Liu J.P. Robertson E.J. Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth Cell 75 1993 73-82
267. Liu J.P. Baker J. Perkins A.S. Robertson E.J. Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-I) and type 1 IGF receptor (IgfIr) Cell 75 1993 59-72
268. Liu J.L. Grinberg A. Westphal H. Sauer B. Accili D. Karas M. LeRoith D. Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice Mol. Endocrinol. 12 1998 1452-1462
269. Sjogren K. Wallenius K. Liu J.L. Bohlooly Y. Pacini G. Svensson L. Tornell J. Isaksson O.G. Ahren B. Jansson J.O. Ohlsson C. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism Diabetes 50 2001 1539-1545
270. Smith T.R. Elmendorf J.S. David T.S. Turinsky J. Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4 Am. J. Physiol. 272 1997 E1071-E1079
271. Thirone A.C. Carvalho C.R. Brenelli S.L. Velloso L.A. Saad M.J. Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues Mol. Cell. Endocrinol. 130 1997 33-42
272. Dominici F.P. Cifone D. Bartke A. Turyn D. Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice Am. J. Physiol. 277 1999 E447-E454
273. Fernandez A.M. Kim J.K. Yakar S. Dupont J. Hernandez-Sanchez C. Castle A.L. Filmore J. Shulman G.I. Le Roith D. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes Genes Dev. 15 2001 1926-1934
274. LeRoith D. Kim H. Fernandez A.M. Accili D. Inactivation of muscle insulin and IGF-I receptors and insulin responsiveness Curr. Opin. Clin. Nutr. Metab. Care 5 2002 371-375
275. Chang P.Y. Goodyear L.J. Benecke H. Markuns J.S. Moller D.E. Impaired insulin signaling in skeletal muscles from transgenic mice expressing kinase-deficient insulin receptors J. Biol. Chem. 270 1995 12593-12600
276. Bruning J.C. Michael M.D. Winnay J.N. Hayashi T. Horsch D. Accili D. Goodyear L.J. Kahn C.R. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance Mol. Cell 2 1998 559-569
277. Shefi-Friedman L. Wertheimer E. Shen S. Bak A. Accili D. Sampson S.R. Increased IGFR activity and glucose transport in cultured skeletal muscle from insulin receptor null mice Am. J. Physiol. 281 2001 E16-E24
278. Ueki I. Ooi G.T. Tremblay M.L. Hurst K.R. Bach L.A. Boisclair Y.R. Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system Proc. Natl. Acad. Sci. USA 97 2000 6868-6873
279. Yakar S. Rosen C.J. Beamer W.G. Ackert-Bicknell C.L. Wu Y. Liu J.L. Ooi G.T. Setser J. Frystyk J. Boisclair Y.R. LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density J. Clin. Invest. 110 2002 771-781
280. Zapf J. Hauri C. Futo E. Hussain M. Rutishauser J. Maack C.A. Froesch E.R. Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats J. Clin. Invest. 95 1995 179-186
281. Firth S.M. McDougall F. McLachlan A.J. Baxter R.C. Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analogue with reduced ternary complex-forming ability Endocrinology 143 2002 1669-1676
282. Lopez M.F. Dikkes P. Zurakowski D. Villa-Komaroff L. Majzoub J.A. Regulation of hepatic glycogen in the insulin-like growth factor II-deficient mouse Endocrinology 140 1999 1442-1448
283. Rogler C.E. Yang D. Rossetti L. Donohoe J. Alt E. Chang C.J. Rosenfeld R. Neely K. Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice J. Biol. Chem. 269 1994 13779-13784
284. Rossetti L. Barzilai N. Chen W. Harris T. Yang D. Rogler C.E. Hepatic overexpression of insulin-like growth factor-II in adulthood increases basal and insulin-stimulated glucose disposal in conscious mice J. Biol. Chem. 271 1996 203-208
285. Modric T. Silha J.V. Shi Z. Gui Y. Suwanichkul A. Durham S.K. Powell D.R. Murphy L.J. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice Endocrinology 142 2001 1958-1967
286. Silha J.V. Gui Y. Murphy L.J. Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice Am. J. Physiol. 283 2002 E937-E945
287. Ricort J.M. Binoux M. Insulin-like growth factor binding protein-3 activates a phosphotyrosine phosphatase J. Biol. Chem. 277 2002 19448-19454
288. Hoeflich A. Wu M. Mohan S. Foll J. Wanke R. Froehlich T. Arnold G.J. Lahm H. Kolb H.J. Wolf E. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain Endocrinology 140 1999 5488-5496
289. Frayling T.M. Hattersley A.T. McCarthy A. Holly J. Mitchell S.M. Gloyn A.L. Owen K. Davies D. Smith G.D. Ben Shlomo Y. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in UK populations Diabetes 51 2002 2313-2316
290. Frayling T.M. Hattersley A.T. Smith G.D. Ben Shlomo Y. Conflicting results on variation in the IGFI gene highlight methodological considerations in the design of genetic association studies Diabetologia 45 2002 1605-1606
291. Rasmussen S.K. Lautier C. Hansen L. Echwald S.M. Hansen T. Ekstrom C.T. Urhammer S.A. Borch-Johnsen K. Grigorescu F. Smith R.J. Pedersen O. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 85 2000 1606-1610
292. Sandhu M.S. Gibson J.M. Heald A.H. Dunger D.B. Wareham N.J. Low circulating IGF-II concentrations predict weight gain and obesity in humans Diabetes 52 2003 1403-1408
293. Knowler W.C. Narayan K.M. Hanson R.L. Nelson R.G. Bennett P.H. Tuomilehto J. Schersten B. Pettitt D.J. Preventing non-insulin-dependent diabetes Diabetes 44 1995 483-488
294. Paolisso G. Tagliamonte M.R. Rizzo M.R. Carella C. Gambardella A. Barbieri M. Varricchio M. Low plasma insulin-like growth factor-1 concentrations predict worsening of insulin-mediated glucose uptake in older people J. Am. Geriatr. Soc. 47 1999 1312-1318
295. Barbieri M. Rizzo M.R. Manzella D. Paolisso G. Age-related insulin resistance: is it an obligatory finding? The lesson from healthy centenarians Diabetes Metab. Res. Rev. 17 2001 19-26
296. Travers S.H. Labarta J.I. Gargosky S.E. Rosenfeld R.G. Jeffers B.W. Eckel R.H. Insulin-like growth factor binding protein-I levels are strongly associated with insulin sensitivity and obesity in early pubertal children J. Clin. Endocrinol. Metab. 83 1998 1935-1939
297. Manetta J. Brun J.F. Maimoun L. Callis A. Prefaut C. Mercier J. Effect of training on the GH/IGF-I axis during exercise in middle-aged men: relationship to glucose homeostasis Am. J. Physiol 283 2002 E929-E936
298. Mohamed-Ali V. Pinkney J.H. Panahloo A. Cwyfan-Hughes S. Holly J.M. Yudkin J.S. Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome Clin. Endocrinol. (Oxf.) 50 1999 221-228
299. De Meyts P. Christoffersen C.T. Urso B. Wallach B. Gronskov K. Yakushiji F. Shymko R.M. Role of the time factor in signaling specificity: application to mitogenic and metabolic signalling by the insulin and insulin-like growth factor-I receptor tyrosine kinases Metabolism 44 1995 2-11
300. Frasca F. Pandini G. Scalia P. Sciacca L. Mineo R. Costantino A. Goldfine I.D. Belfiore A. Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells Mol. Cell. Biol. 19 1999 3278-3288
301. Hussain M.A. Schmitz O. Mengel A. Keller A. Christiansen J.S. Zapf J. Froesch E.R. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans J. Clin. Invest. 92 1993 2249-2256
302. Crowne E.C. Samra J.S. Cheetham T. Watts A. Holly J.M. Dunger D.B. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus Metabolism 47 1998 31-38
303. Moses A.C. Young S.C. Morrow L.A. O'Brien M. Clemmons D.R. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes Diabetes 45 1996 91-100
304. Pratipanawatr T. Pratipanawatr W. Rosen C. Berria R. Bajaj M. Cusi K. Mandarino L. Kashyap S. Belfort R. DeFronzo R.A. Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects Am. J. Physiol. 282 2002 E1360-E1368
305. O'Connell T. Clemmons D.R. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms J. Clin. Endocrinol. Metab. 87 2002 4356-4360
306. Silfen M.E. Manibo A.M. Ferin M. McMahon D.J. Levine L.S. Oberfield S.E. Elevated free IGF-I levels in prepubertal Hispanic girls with premature adrenarche: relationship with hyperandrogenism and insulin sensitivity J. Clin. Endocrinol. Metab. 87 2002 398-403
307. Hoeflich A. Reisinger R. Lahm H. Kiess W. Blum W.F. Kolb H.J. Weber M.M. Wolf E. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res. 61 2001 8601-8610
308. Riedel M. Hoeft B. Blum W.F. von zur Muhlen A. Brabant G. Pulsatile growth hormone secretion in normal-weight and obese men: differential metabolic regulation during energy restriction Metabolism 44 1995 605-610
309. Bang P. Nygren J. Carlsson S.C. Thorell A. Ljungqvist O. Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity J. Clin. Endocrinol. Metab. 83 1998 2509-2515
310. Nygren J. Carlsson-Skwirut C. Brismar K. Thorell A. Ljungqvist O. Bang P. Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery Am. J. Physiol. 281 2001 E736-E741
311. Kahn C.R. The riddle of tumour hypoglycaemia revisited Clin. Endocrinol. Metab. 9 1980 335-360
312. Daughaday W.H. The pathophysiology of IGF-II hypersecretion in non-islet cell tumor hypoglycemia Diabetes Rev. 3 1995 62-72
313. Zapf J. Insulinlike growth factor binding proteins and tumor hypoglycemia Trends Endocrinol. Metab. 6 1995 37-42
314. Baxter R.C. The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia Horm. Res. 46 1996 195-201
315. Zapf J. Futo E. Peter M. Froesch E.R. Can big insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J. Clin. Invest. 90 1992 2574-2584
316. Baxter R.C. Holman S.R. Corbould A. Stranks S. Ho P.J. Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia J. Clin. Endocrinol. Metab. 80 1995 2700-2708
317. Baxter R.C. Daughaday W.H. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors J. Clin. Endocrinol. Metab. 73 1991 696-702
318. Daughaday W.H. Trivedi B. Baxter R.C. Abnormal serum IGF-II transport in non-islet cell tumor hypoglycemia results from abnormalities of both IGF binding protein-3 and acid labile subunit and leads to elevation of free IGF-II Endocrine 3 1995 425-430
319. Møller N. Frystyk J. Skjærbæk C. Pedersen H.B. Christensen C. Schmitz O. Gee A. Gjedde A. Zapf J. Ørskov H. Systemic and regional tumour metabolism in a patient with non-islet cell tumour hypoglycaemia: role of increased levels of free insulin-like growth factors Diabetologia 39 1996 1534-1535
320. Chen J.W. Ledet T. Ørskov H. Jessen N. Lund S. Whittaker J. De Meyts P. Larsen M.B. Christiansen J.S. Frystyk J. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum Am. J. Physiol. 284 2003 E1149-E1155
321. Sadick M.D. Sliwkowski M.X. Nuijens A. Bald L. Chiang N. Lofgren J.A. Wong W.L. Analysis of heregulin-induced ErbB2 phosphorylation with a high-throughput kinase receptor activation enzyme-linked immunosorbant assay Anal. Biochem. 235 1996 207-214
322. Sadick M.D. Kinase receptor activation (KIRA): a rapid and accurate alternative to endpoint bioassays Dev. Biol. Stand. 97 1999 121-133
323. Hasegawa Y. Hasegawa T. Takada M. Tsuchiya Y. Plasma free insulin-like growth factor I concentrations in growth hormone deficiency in children and adolescents Eur. J. Endocrinol. 134 1996 184-189
324. Skjærbæk C. Vahl N. Frystyk J. Hansen T.B. Jørgensen J.O. Hagen C. Christiansen J.S. Ørskov H. Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement Eur. J. Endocrinol. 137 1997 132-137
325. Juul A. Andersson A.M. Pedersen S.A. Jørgensen J.O. Christiansen J.S. Groome N.P. Skakkebæk N.E. Effects of growth hormone replacement therapy on IGF-related parameters and on the pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study Horm. Res. 49 1998 269-278
326. Musolino N.R. Cunha Neto M.B. Marino J.R. Giannella-Neto D. Bronstein M.D. Evaluation of free insulin-like growth factor-I measurement on the diagnosis and follow-up treatment of growth hormone-deficient adult patients Clin. Endocrinol. (Oxf.) 50 1999 441-449
327. Støving R.K. Andersen M. Flyvbjerg A. Frystyk J. Hangaard J. Vinten J. Koldkjaer O.G. Hagen C. Indirect evidence for decreased hypothalamic somatostatinergic tone in anorexia nervosa Clin. Endocrinol. (Oxf.) 56 2002 391-396